Pace® Aerobiology Receives AIHA EMLAP Accreditation for Washington State Laboratory
08 févr. 2023 09h00 HE
|
Pace Analytical
MINNEAPOLIS, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aerobiology, part of the Pace® Analytical Services laboratory network, today announced that its Seattle, Washington, laboratory has achieved...
Pace® Aerobiology Receives AIHA EMLAP Accreditation for Washington State Laboratory
08 févr. 2023 09h00 HE
|
Pace Analytical
MINNEAPOLIS, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aerobiology, part of the Pace® Analytical Services laboratory network, today announced that its Seattle, Washington, laboratory has achieved...
Occupational Health and Safety (Industrial Hygiene) Experts Clarify Misinformation on PPE, Ventilation, and Disinfection in Relation to COVID-19
16 avr. 2020 08h00 HE
|
AIHA
Falls Church, VA, April 16, 2020 (GLOBE NEWSWIRE) -- As the COVID-19 pandemic spreads across the globe, so does misinformation on personal protective equipment (PPE), decontamination and indoor air...
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
15 juin 2019 10h00 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Groundbreaking Legionella Prevention Model Reported
16 avr. 2019 10h51 HE
|
AIHA
Falls Church (VA), April 16, 2019 (GLOBE NEWSWIRE) -- A groundbreaking hazard analysis formula showcased in the April 2019 issue of The Synergist, the magazine of the American Industrial Hygiene...
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
28 févr. 2019 10h00 HE
|
Apellis Pharmaceuticals, Inc.
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide...
Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
05 févr. 2019 12h02 HE
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky., and WALTHAM, Mass., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
03 déc. 2018 13h01 HE
|
Apellis Pharmaceuticals, Inc.
- New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) - CAD patients treated with APL-2 had...
Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
02 déc. 2018 12h01 HE
|
Apellis Pharmaceuticals, Inc.
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...
Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
13 nov. 2018 08h00 HE
|
Apellis Pharmaceuticals, Inc.
- Commenced Phase 3 Program of APL-2 in Geographic Atrophy (GA) - - Cash Position of $220.6 Million at Quarter-End - CRESTWOOD, Ky. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Apellis...